<< Back to News

System Formulary Update
Rifamycins

Situation

The rifamycins class review standardization was approved in March 2023 by the Systems P&T Committee meeting.

Background

The following products were reviewed: rifabutin capsules, rifabutin oral suspension, rifampin capsules, rifampin oral suspension, rifampin powder for injection, rifamycin delayed release tablets, rifapentin tablets, rifaximin tablets, and rifaximin oral suspension.

Assessment/Recommendations

System P&T voted to include the following products on the UNC Health System Drug Formulary:

• Rifabutin 150 mg capsules
• Rifampin 150 mg capsules
• Rifampin 300 mg capsules
• Rifampin 25 mg/mL oral suspension (extemporaneous)
• Rifampin 600 mg powder for injection
• Rifaximin 200 mg tablets
• Rifaximin 550 mg tablets
• Rifaximin 20 mg/mL oral suspension (extemporaneous)

As a result, the following products will be removed from the inpatient drug formulary:

• Rifabutin 20 mg/mL oral suspension (extemporaneous)
• Rifampin 10 mg/mL oral suspension (extemporaneous)
• Rifamycin 194 mg delayed release tablets
• Rifapentin 150 mg tablets

Note: Stock of this formulary product may vary at individual entities

Formulary/Epic changes will Go-Live on Tuesday, May 16, 2023.